Skip to main content
Clinical Trials/NCT05848024
NCT05848024
Active, Not Recruiting
N/A

Prospective, Single-Center, Non-Controlled, Non-Randomized, Open Study Evaluating the Performance and Stability of Amistem® C

Medacta International SA1 site in 1 country100 target enrollmentFebruary 8, 2017

Overview

Phase
N/A
Intervention
Not specified
Conditions
Total Hip Arthroplasty
Sponsor
Medacta International SA
Enrollment
100
Locations
1
Primary Endpoint
Assess the femoral stem migration
Status
Active, Not Recruiting
Last Updated
7 months ago

Overview

Brief Summary

Primary objective: Evaluate femoral stem migration Secondary objective: Evaluate the performance of AMIStem H Proximal Coating at 10 years after surgery; assessment of functional recovery; radiological evaluation; reporting of complications

Scores collected:

HHS, OHS, PMA, UCLA

Detailed Description

The main objective of the study was to evaluate the migration and performance of the AMIStem® C femoral stem at 10 years follow-up. The primary endpoint is the measurement of femoral component migration by EBRA-FCA (The Ein Bild Roentgen Analyse-femoral component analysis, Innsbruck, Austria) The secondary objectives of the study are: Evaluate the performance of the AMIStem® C stem Evaluate the function of the operated hip To evaluate the quality of life To evaluate the safety of the AMIStem® C femoral stem Evaluate the postoperative stability and fixation of the hip prosthesis

Registry
clinicaltrials.gov
Start Date
February 8, 2017
End Date
February 1, 2029
Last Updated
7 months ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Assess the femoral stem migration

Time Frame: 2 years

The primary endpoint is the measurement of femoral component migration by EBRA-FCA software (The Ein Bild Roentgen Analyse-femoral component analysis, Innsbruck, Austria) with an accuracy of ± 1.5 mm (95% percentile), a specificity of 100% and a sensitivity of 78% for the detection of a migration of more than 1.0 mm, referring to the RSA method. The EBRA-FCA method is based on the detection of 19 points on the bony femur and the femoral component, as well as two lines to determine the axis of the implant on successive radiographs of the front pelvis. The correction of the radiological enlargement is performed based on the known diameter of the prosthetic femoral component. Lengths are measured from anatomical reference points to ensure comparability of the radiographs. The change in the distance between the top of the greater trochanter and the shoulder of the prosthesis is used to measure the migration of the femoral component.

Secondary Outcomes

  • Radiological analysis(pre-op, 7 days, 6 weeks, 3 months, 6 months, 1 year, 2 years, 5 years and 10 years)
  • Assess the Quality of Life of patients(pre-op, 7 days, 6 weeks, 3 months, 6 months, 1 year, 2 years, 5 years and 10 years)
  • Assess the security of AMIStem C and collect complications(pre-op, 7 days, 6 weeks, 3 months, 6 months, 1 year, 2 years, 5 years and 10 years)
  • Assess the postoperative stability and fixation of AMIStem C(pre-op, 7 days, 6 weeks, 3 months, 6 months, 1 year, 2 years, 5 years and 10 years)
  • Assess the AMIStem C performance at 10 years(10 years)
  • Assess the functionality of the operated hip(pre-op, 7 days, 6 weeks, 3 months, 6 months, 1 year, 2 years, 5 years and 10 years)

Study Sites (1)

Loading locations...

Similar Trials